Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Electrospray ionization mass spectrometry as a valuable tool in the characterization of novel primaquine peptidomimetic derivatives
Publication

Publications

Electrospray ionization mass spectrometry as a valuable tool in the characterization of novel primaquine peptidomimetic derivatives

Title
Electrospray ionization mass spectrometry as a valuable tool in the characterization of novel primaquine peptidomimetic derivatives
Type
Article in International Scientific Journal
Year
2009
Authors
Joana Matos
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Rui Moreira
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Vol. 15
Pages: 627-640
ISSN: 1469-0667
Publisher: IM PUBLICATIONS
Scientific classification
FOS: Natural sciences > Chemical sciences
Other information
Authenticus ID: P-003-PXC
Abstract (EN): Novel primaquine-derived antimatarial!, have been extensively characterized by electrospray ionization-ion trap mass spectrometry (ESI-MS). Experiments by in-source collision-induced dissociation (CID) in the nozzle-skimmer region (NSR) or by tandem mass spectrometry (MS/MS) are shown to be most valuable tools for the physico-chemical. characterization of these 8-aminoquinolinic drugs that also bear the biologically relevant midazolidin-4-one scaffold. It was possible to find parallelism between compound stability in the NSR and its reactivity towards hydrolysis at physiological pH and T. Moreover, MS/MS fragmentation patterns were characteristic for each family, providing a means for structural. distinction of isomers and allowing interesting correlations to be found between the relative abundance of particular fragments and relevant structure-activity determinants, such as the Charton steric parameter, nu. In conclusion, this work provides a solid ground for establishing ESI-MS as a key toot for the physico-chemical characterization of biopharmaceuticals bearing the 8-aminoqunoline and/or the imidazolidin-4-one moieties.
Language: English
Type (Professor's evaluation): Scientific
License type: Click to view license CC BY-NC
Documents
File name Description Size
ART_50 976.29 KB
Related Publications

Of the same authors

Primacenes: on the way to novel organometallic antimalarials (2010)
Summary of Presentation in a National Conference
Joana Matos; Filipa Cruz; Elia Cabrita; Fátima Nogueira; Nuno Vale; Rui Moreira; Virgílio do Rosário; Maria Mota; Miguel Prudêncio; Paula Gomes
PRIMACENES: novel non-cytotoxic primaquine-ferrocene conjugates with anti-Pneumocystis carinii activity (2010)
Article in International Scientific Journal
Joana Matos; Nuno Vale; Margaret S Collins; Jiri Gut; Philip J Rosenthal; Melanie T Cushion; Rui Moreira; Paula Gomes
Peptidomimetic and Organometallic Derivatives of Primaquine Active against Leishmania infantum (2012)
Article in International Scientific Journal
Silvia Vale Costa; Nuno Vale; Joana Matos; Ana Tomas; Rui Moreira; Paula Gomes; Maria Salome Gomes
Imidazoquines as Antimalarial and Antipneumocystis Agents (2009)
Article in International Scientific Journal
Nuno Vale; Miguel Prudencio; Catarina A Marques; Margaret S Collins; Jiri Gut; Fatima Nogueira; Joana Matos; Philip J Rosenthal; Melanie T Cushion; Virgilio E do Rosario; Maria M Mota; Rui Moreira; Paula Gomes
Imidazolidin-4-one peptidomimetic derivatives of primaquine: Synthesis and antimalarial activity (2008)
Article in International Scientific Journal
Nuno Vale; Joana Matos; Jiri Gut; Fatima Nogueira; Virgilio do Rosario; Philip J Rosenthal; Rui Moreira; Paula Gomes

See all (7)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-08-06 at 04:14:50 | Privacy Policy | Personal Data Protection Policy | Whistleblowing